You are here

Preclinical Development of OCF001 for Treatment of Yeast Infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI131792-02A1
Agency Tracking Number: R42AI131792
Amount: $1,948,860.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-03-21
Award End Date (Contract End Date): 2022-04-30
Small Business Information
606 COACHLIGHT CT
College Station, TX 77845-8145
United States
DUNS: 078514829
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES SMITH
 (855) 384-7266
 jsmith@sanochemicals.com
Business Contact
 JAMES SMITH
Phone: (979) 845-2417
Email: james.smith@sanochemicals.com
Research Institution
 TEXAS A&M UNIVERSITY
 
400 HARVEY MITCHELL PARKWAY SOUTH
COLLEGE STATION, TX 77845-4375
United States

 Nonprofit college or university
Abstract

Project Summary
Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with
submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production
and isolation of occidiofungins from liquid cultures has been performed. The production and
isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial
development as a novel antifungal therapeutic. Several of the benchmarks used to evaluate the
development of a novel therapeutic have been met with OCF001. OCF001 is a potent antifungal
against fluconazole and caspofungin-resistant Candida species. It was also shown to be effective
at inhibiting Candida auris at 0.25 g/ml. The antifungal triggers cell death by inducing apoptosis
in yeast cells and was shown to have minimal toxicity in mice dosed with 2 mg/kg in a 28-day
toxicity study. Furthermore, OCF001 was demonstrated to be an effective antifungal treatment for
vaginal yeast infections in mice. All these studies point to the need to further the preclinical
development of this novel compound. OCF001, along with very few antifungal compounds, have
met any of these benchmarks, and therefore it holds promise as a potential antifungal therapeutic
agent. The goal of this application is to complete the pre-Investigational New Drug (pre-IND)
enabling and IND enabling studies for the development of an antifungal product for the treatment
of systemic and vaginal yeast infections.Project Narrative
The proposal addresses the need for the development of novel broad-spectrum antifungal
products for vulvovaginal yeast and invasive yeast infections. The studies proposed are essential
for filing two Investigational New Drug Applications (INDAs).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government